Cannabis-based drug in further trials
Monday 15th February 2016
A drug assessed in a Phase 1 trial at NIHR Leeds CRF has now moved on to further trials in the USA and Europe.
The drug, dexanabinol, is a synthetic cannabinoid – a derivative of cannabis – which had previously been assessed for use in patients with head trauma. Oxford-based drug discovery and development group, E-therapeutics, is now looking to develop dexanabinol for use in cancer. Our faility was one of three UK centres which worked with E-therapeutics on the Phase 1a trial of the drug.
The trial recruited patients with a variety of solid tumours, with the aim of establishing an appropriate dose for the next phase of development. The trial assessed how the drug was acting in the body, safety and tolerability in patients and whether any initial signs of anti-cancer activity could be identified.
Further studies with Dexanabinol in pancreatic and liver cancers are underway in sites across Europe.